Pharmacology: Pharmacodynamics: The mechanism of anti-inflammatory action of benzydamine is not related to stimulation of the pituitary-adrenal axis. Like other non-steroidal anti-inflammatory agents, benzydamine inhibits the biosynthesis of prostaglandins under certain conditions, but its properties in this respect have not been fully elucidated. The stabilising effect on cellular membranes may also be involved in the mechanism of action.
Benzydamine is an anti-inflammatory analgesic agent structurally unrelated to the steroid group. Benzydamine differs chemically from other non-steroidal anti-inflammatory agents in that it is a base rather than an acid.
Pharmacokinetics: Benzydamine is well absorbed following oral administration. Following topical administration, benzydamine is well absorbed into the inflamed local mucosa where it exerts anti-inflammatory and local anaesthetic actions. Plasma benzydamine levels following use are low and proportionate to the amount actually ingested.
Benzydamine and its metabolites are excreted largely in the urine. Metabolism is largely excreted by oxidative pathways, although dealkylation can be shown.
Benzydamine has been detected in blood and urine following gargling of solution form. Most of the absorbed dose is eliminated in the first 24 hours. Repeated administration for 7 days does not result in accumulation of benzyldamine in plasma.